This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Alexion Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01567085
First received: March 27, 2012
Last updated: October 21, 2016
Last verified: October 2016
  Purpose

Primary Objective:

To evaluate the safety and potential efficacy of eculizumab to prevent Antibody Mediated Rejection (AMR) in sensitized recipients of deceased donor kidney transplants.


Condition Intervention Phase
Stage V Chronic Kidney Disease Drug: Eculizumab Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Single-Arm, Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection (AMR) in Sensitized Recipients of a Kidney Transplant From a Deceased Donor.

Resource links provided by NLM:


Further study details as provided by Alexion Pharmaceuticals:

Primary Outcome Measures:
  • Post-transplantation treatment failure rate [ Time Frame: 12 months ]

Enrollment: 80
Study Start Date: May 2012
Estimated Study Completion Date: June 2017
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eculizumab Drug: Eculizumab

Eculizumab 1200 mg (4 vials) administered intravenously (IV) over 35 to 45 minutes.

Eculizumab 900 mg (3 vials) administered IV over 35 to 45 minutes.


  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients ≥ 18 years old
  2. Patients with Stage V chronic kidney disease who will receive a kidney transplant from a deceased donor to whom they are sensitized
  3. History of prior exposure to HLA (Human Leukocyte Antigen):

    • Prior solid organ or tissue allograft
    • Pregnancy
    • Blood transfusion
    • Prior exposure to specific donor's HLA

Exclusion Criteria:

  1. Has received treatment with eculizumab at any time prior to enrolling in this study
  2. ABO (A,B and O Blood Glycoproteins-Blood Type) incompatible with deceased donor
  3. History of severe cardiac disease
  4. Prior splenectomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01567085

Locations
Australia
Camperdown, Australia, 2050
North Terrace, Australia, 5000
Parkville VIC, Australia, 3050
France
Bordeaux, France, 33076
Paris, France, 75010
Paris, France, 75743
Toulouse, France, 31059
Tours, France, 37044
Italy
Brescia, Italy, 25123
Padova, Italy, 35128
Spain
Barcelona, Spain, 08907
Sweden
Gothenburg, Sweden, 413 45
Upsala, Sweden, 751 85
United Kingdom
Cambridge, United Kingdom, CB2 2QQ
London, United Kingdom, SE1 9RT
Sponsors and Collaborators
Alexion Pharmaceuticals
  More Information

Responsible Party: Alexion Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01567085     History of Changes
Other Study ID Numbers: C10-002
2010-019631-35 ( EudraCT Number )
Study First Received: March 27, 2012
Last Updated: October 21, 2016

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency

ClinicalTrials.gov processed this record on July 27, 2017